Document Type Document Type Total other expense Other Nonoperating Income (Expense) Funding during the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Related Party [Axis] Related Party [Axis] Treasury Stock Treasury Stock [Member] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Accrued expenses and other current liabilities. Level 3 Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Potential milestones payment receivable Potential Milestones Payment Receivable Potential Milestones Payment Receivable Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities and stockholders' equity (deficit) Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Development Derivative Liability Derivative Instruments and Hedging Activities Disclosure [Text Block] Security Exchange Name Security Exchange Name SBIR Grants Small Business Innovation Research Grants [Member] Small business innovation research grants. Loss from operations Operating Income (Loss) Tranche 1, 2, and 3 Tranche 1, 2, and 3 [Member] Tranche 1, 2, and 3 [Member] Total current liabilities Liabilities, Current Prepaid expenses and other assets Prepaid Expense and Other Assets, Current License Agreements [Line Items] License Agreements [Line Items] License Agreements. Variable Rate [Domain] Variable Rate [Domain] Variable Rate [Axis] Variable Rate [Axis] Cash and Cash Equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Commitments and contingencies (Note 8) Commitments and Contingencies Assets Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Furniture and fixtures Furniture and Fixtures [Member] Entity Address, State or Province Entity Address, State or Province Achievement Of Clinical Development And Regulatory Milestones Achievement Of Clinical Development And Regulatory Milestones [Member] Achievement of clinical development and regulatory milestones. Warrants to purchase common stock Warrants To Purchase Common Stock [Member] Warrants to purchase common stock. Common stock options Common Stock Options [Member] Common stock options. Accounts payable Accounts Payable, Current Accrued Expenses and Other Current Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Organization And Description Of Business [Table] Organization And Description Of Business [Table] Organization and description of business. Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Debt discount Debt Instrument, Unamortized Discount 2022 Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Summary of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Preferred stock, $0.001 par value; 10,000,000 shares authorized; zero shares issued and outstanding at March 31, 2021 and December 31, 2020 Preferred Stock, Value, Issued Income Taxes Income Tax, Policy [Policy Text Block] Number of purchase periods Share-based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods Share-based Compensation Arrangement by Share-based Payment Award, Number of Purchase Periods Initial payment received for license agreement Initial Payment Received For License Agreement Initial Payment Received For License Agreement Total operating expenses Operating Expenses Duke University Duke University [Member] Duke university. Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Percentage of employee's compensation, maximum Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Employee's Compensation Maximum Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Employee's Compensation Maximum Organization and Description of Business [Line Item] Organization And Description Of Business [Line Items] Organization and description of business. Other long-term liabilities Other Liabilities, Noncurrent Sale of licensed products or services Sale Of Licensed Products Or Services Sale of licensed products or services. Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Pharmaceuticals And Medical Devices Agency Of Japan And National Medical Productions Administration Of China Pharmaceuticals And Medical Devices Agency Of Japan And National Medical Productions Administration Of China [Member] Pharmaceuticals And Medical Devices Agency Of Japan And National Medical Productions Administration Of China [Member] Revenue Revenue from Contract with Customer, Excluding Assessed Tax Derivative Derivative [Member] Measurement Frequency [Domain] Measurement Frequency [Domain] Lender Name [Axis] Lender Name [Axis] Tranche B Tranche B [Member] Tranche B. Statement [Line Items] Statement [Line Items] Schedule of Outstanding Potentially Dilutive Securities Excluded in Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Tranche 1 Tranche 1 [Member] Tranche 1 [Member] Class of Stock [Domain] Class of Stock [Domain] Fees payment Payments for Other Fees Milestone payment Milestone Payment Milestone Payment Accrued interest Interest Payable, Current Offering period (in months) Share-based Compensation Arrangement by Share-based Payment Award, Offering Period Share-based Compensation Arrangement by Share-based Payment Award, Offering Period Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Development derivative liability Derivative Liability, Noncurrent Exercise price of warrant (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Significant Accounting Policies [Table] Significant Accounting Policies [Table] Significant accounting policies. Net loss per common share, basic and diluted (in usd per share) Earnings Per Share, Basic and Diluted Entity Small Business Entity Small Business Aggregate offering price Aggregate Offering Price Of Common Stock, Preferred Stock, Debt Securities And Warrants Aggregate Offering Price Of Common Stock, Preferred Stock, Debt Securities And Warrants Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Proceeds from issuance of common stock in public offering, net Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Amendment Flag Amendment Flag Balance at December 31, 2020 Balance at March 31, 2021 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Research and Development Expense Research and Development Expense, Policy [Policy Text Block] Accrued other Other Accrued Liabilities, Current Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Tranche 3 Tranche 3 [Member] Tranche 3 [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Central Index Key Entity Central Index Key Related Party [Domain] Related Party [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Stock-Based Compensation Compensation Related Costs, Policy [Policy Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Purchase obligation, year 2024 Purchase Obligation, to be Paid, Year Four Development Derivative Liabilities Derivatives, Policy [Policy Text Block] Purchases of property and equipment included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Option to extend (in years) Lessee, Operating Lease, Renewal Term Number of additional annual payments Number Of Additional Annual Payments Number Of Additional Annual Payments Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Employee stock purchase plan ESPP Employee Stock [Member] Income Statement Location [Axis] Income Statement Location [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Purchases of property and equipment by incurring development derivative liability Capital Expenditures Incurred but Not yet Paid, Incurring Development Derivative Liability Capital Expenditures Incurred but Not yet Paid, Incurring Development Derivative Liability Financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Other assets Other Assets, Noncurrent Issuance of common stock in public offering, net Stock Issued During Period, Value, New Issues Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Tranche A Tranche A [Member] Tranche A. Total assets Assets Related Party Transactions Related Party Transactions Disclosure [Text Block] Purchase obligation, year 2025 through 2031 Purchase Obligation, to be Paid, Year Five Through Eleven Purchase Obligation, to be Paid, Year Five Through Eleven Initial liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Interest expense Interest Expense, Debt Title of 12(b) Security Title of 12(b) Security Schedule of Composition of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] License Agreements [Abstract] License Agreements [Abstract] License agreements. Interest expense Interest Expense Initial payment for license Initial Payment For License Agreement Initial Payment For License Agreement Product and Service [Axis] Product and Service [Axis] Total liabilities Liabilities United States Food And Drug Administration United States Food And Drug Administration [Member] United States Food And Drug Administration [Member] Weighted-average period expected to be recognized (in years) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Proceeds from issuance of common stock, deducting underwriting discounts, commissions, and other offering costs Proceeds from Issuance of Common Stock, Excluding Underwriting Discounts, Commissions, and Other Offering Costs Proceeds from Issuance of Common Stock, Excluding Underwriting Discounts, Commissions, and Other Offering Costs Less: Present value adjustment Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2023 Long-Term Debt, Maturity, Year Two Licenses and Other Agreements License Agreement [Text Block] License agreement. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Issuance of warrants in conjunction with development derivative liability Issuance of Stock and Warrants for Derivative Instruments Issuance of Stock and Warrants for Derivative Instruments Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Aggregate offering price, remaining Aggregate Offering Price Of Common Stock, Preferred Stock, Debt Securities And Warrants, Remaining Aggregate Offering Price Of Common Stock, Preferred Stock, Debt Securities And Warrants, Remaining Equity Distribution Agreement with Citigroup Global Markets Inc. and William Blair & Company, L.L.C. Equity Distribution Agreement with Citigroup Global Markets Inc. and William Blair & Company, L.L.C. [Member] Equity Distribution Agreement with Citigroup Global Markets Inc. and William Blair & Company, L.L.C. [Member] Accounts payable Increase (Decrease) in Accounts Payable Regulatory Agency [Axis] Regulatory Agency [Axis] Additional payment received for license agreement Additional Payment Received For License Agreement Additional Payment Received For License Agreement Debt Instrument [Axis] Debt Instrument [Axis] Additional Paid-in Capital Additional Paid-in Capital [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Class of Stock [Line Items] Class of Stock [Line Items] Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Development derivative liability (Note 7) Derivative Liability Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding License agreement upfront payment License Agreement Upfront Payment License agreement upfront payment. Proceeds from development derivative liability Payments for (Proceeds from) Derivative Instrument, Financing Activities Research and development Research and Development Expense Common stock, shares authorized (in shares) Common Stock, Shares Authorized Property and equipment, gross Property, Plant and Equipment, Gross Proceeds from exercise of stock options Proceeds from Stock Options Exercised Income Statement [Abstract] Income Statement [Abstract] Operating lease liabilities, net Operating Lease, Liability, Noncurrent Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Nonroyalty payment received Nonroyalty Payment Received Nonroyalty payment received. Less unamortized loan fees Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Use of Estimates Use of Estimates, Policy [Policy Text Block] Current assets: Assets, Current [Abstract] Non-cash research and development expense Noncash or Part Noncash, Research and Development Expense Noncash or Part Noncash, Research and Development Expense Interest income Investment Income, Interest Proceeds from partnership contribution Proceeds from Partnership Contribution Additional payment for license Additional Payment For License Agreement Additional Payment For License Agreement Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share 2022 Long-Term Debt, Maturity, Year One Counterparty Name [Domain] Counterparty Name [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Document Period End Date Document Period End Date License Agreements [Table] License Agreements [Table] License agreements. Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Stock offering costs included in accounts payable and accrued expenses Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Viamet Pharmaceuticals Holdings, LLC Viamet Pharmaceuticals Holdings, LLC [Member] Viamet Pharmaceuticals Holdings, LLC [Member] Number of tranches Number of Tranches Number of Tranches Stock-based compensation Share-based Payment Arrangement, Noncash Expense 2021 (remaining nine months) Long-Term Debt, Maturity, Remainder of Fiscal Year Cover [Abstract] Property and equipment estimated useful lives (in years) Property, Plant and Equipment, Useful Life Total term loan borrowings Long-term Debt Leases Lessee, Operating Leases [Text Block] Other non-cash transactions Other Noncash Expense Accrued clinical and related costs Accrued Clinical And Related Costs Current Accrued clinical and related costs current. Aggregate offering price Sale of Stock, Stock, Debt and Warrants, Amount Authorized Sale of Stock, Stock, Debt and Warrants, Amount Authorized Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Equity Components [Axis] Equity Components [Axis] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] European Medicines Agency European Medicines Agency [Member] European Medicines Agency [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Operating lease liability, short-term Operating Lease, Liability, Current ATM Program At-the-Market Program [Member] At-the-Market Program Grants from the National Institutes of Health Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Entity Interactive Data Current Entity Interactive Data Current Percentage of final payment on principal amount of refinanced advances Percentage Of Final Payment On Principal Amount Of Refinanced Advances Percentage of final payment on principal amount of refinanced advances. Fair Value Measurement Fair Value Disclosures [Text Block] Operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Stockholders’ Equity Stockholders' Equity Note Disclosure [Text Block] Entity Registrant Name Entity Registrant Name Derivative [Table] Derivative [Table] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Weighted average discount rate used to determine the right-of-use assets and corresponding operating lease liabilities Operating Lease, Weighted Average Discount Rate, Percent Assets Assets, Fair Value Disclosure [Abstract] SVB and WestRiver Silicon Valley Bank And West River Innovation Lending Fund [Member] Silicon Valley Bank and West River Innovation Lending Fund Member. Commercial Milestones Commercial Milestones [Member] Commercial milestones. Schedule of Development Derivative Liability Schedule of Derivative Liabilities at Fair Value [Table Text Block] Other income (expense): Other Nonoperating Income (Expense) [Abstract] Research and development Research and Development Expense [Member] Non-cash interest expense Paid-in-Kind Interest Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Thereafter Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Shares issued (in usd per share) Shares Issued, Price Per Share Purchase period, term Share-based Compensation Arrangement by Share-based Payment Award, Purchase Period, Term Share-based Compensation Arrangement by Share-based Payment Award, Purchase Period, Term Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Sale of Stock [Axis] Sale of Stock [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Weighted average common shares outstanding, basic, and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Percentage of lower of fair market value Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Document Transition Report Document Transition Report Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Document Quarterly Report Document Quarterly Report Liabilities Liabilities, Fair Value Disclosure [Abstract] General and administrative General and Administrative Expense [Member] Supplemental disclosure of non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Entity File Number Entity File Number Debt Disclosure [Abstract] Debt Disclosure [Abstract] Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Common stock, shares issued term Common Stock, Issued, Term Common Stock, Issued, Term Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Repayments of long-term debt Repayments of Long-term Debt Issuance of common stock warrants Adjustments to Additional Paid in Capital, Warrant Issued Total stock-based compensation Stock-based compensation expense Share-based Payment Arrangement, Expense Counterparty Name [Axis] Counterparty Name [Axis] Common stock, $0.001 par value; 200,000,000 shares authorized; 47,982,000 shares issued and 47,952,033 shares outstanding at March 31, 2021; 29,471,854 shares issued and 29,441,887 shares outstanding at December 31, 2020 Common stock, shares issued, value Common Stock, Value, Issued Document Fiscal Year Focus Document Fiscal Year Focus Current portion of long-term debt Long-term Debt, Current Maturities Entity Current Reporting Status Entity Current Reporting Status Common stock, public offering price (in usd per share) Sale of Stock, Price Per Share Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Interest rate Cost of borrowing rate Debt Instrument, Interest Rate During Period Working capital Working Capital Working capital. Aggregate royalties payment Payments for Royalties Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] bentracimab Bentracimab [Member] Bentracimab Investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Revenue from Contract with Customer, Product and Service [Extensible List] Revenue from Contract with Customer, Product and Service [Extensible List] Operating lease liabilities Operating Lease, Liability SFJ Agreement SFJ Agreement [Member] SFJ Agreement [Member] Long-term debt, net Long-term Debt, Excluding Current Maturities Debt Instrument [Line Items] Debt Instrument [Line Items] Total stockholders’ equity (deficit) Beginning balance Ending balance Stockholders' Equity Attributable to Parent March 2021 Offering March 2021 Offering [Member] March 2021 Offering Payments of deferred stock offering costs Payments of Stock Issuance Costs SFJ Pharmaceuticals X, Ltd. SFJ Pharmaceuticals X, Ltd. [Member] SFJ Pharmaceuticals X, Ltd. [Member] Term Loan Term Loan [Member] Term loan. Total liabilities and stockholders' equity (deficit) Liabilities and Equity Entity Address, City or Town Entity Address, City or Town Accrued compensation and related costs Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Acquisition of intellectual property rights Payments to Acquire Intangible Assets Rent expense Operating Lease, Cost General and administrative General and Administrative Expense Financial Instrument [Axis] Financial Instrument [Axis] Outstanding potentially dilutive securities excluded in calculation of diluted net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Tranche 2 Tranche 2 [Member] Tranche 2 [Member] Entity Ex Transition Period Entity Ex Transition Period Preclinical and Clinical Trial Accruals Preclinical And Clinical Trial Accruals Policy [Text Block] Preclinical and clinical trial accruals. Equity Component [Domain] Equity Component [Domain] Common stock purchased (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Construction in progress Construction in Progress [Member] Entity Tax Identification Number Entity Tax Identification Number Stock-Based Compensation Share-based Payment Arrangement [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Other receivables Increase (Decrease) in Other Receivables Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] 2021 (remaining nine months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Leases [Abstract] Leases [Abstract] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date Operating expenses: Operating Expenses [Abstract] Amortization period of payments of principal plus interest amounts Amortization Period Of Payments Of Principal Plus Interest Amounts Amortization period of payments of principal plus interest amounts. Stockholders’ equity (deficit): Stockholders' Equity Attributable to Parent [Abstract] Number of warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Document Fiscal Period Focus Document Fiscal Period Focus Supplemental disclosure for cash flow Supplemental Cash Flow Information [Abstract] Entity Filer Category Entity Filer Category Stock-based Compensation Expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Common Stock Common Stock [Member] SFJ Pharmaceuticals SFJ Pharmaceuticals [Member] SFJ Pharmaceuticals [Member] Product and Service [Domain] Product and Service [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Composition of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Issuance of common stock in public offering, net (in shares) Common stock, shares, issued and sold Stock Issued During Period, Shares, New Issues Leasehold improvements Leasehold Improvements [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Significant accounting policies. Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Exercises of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Related Party Transactions [Abstract] Related Party Transactions [Abstract] Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Employee Stock Option Share-based Payment Arrangement, Option [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Expiration term Class of Warrant or Right, Expiration Term Class of Warrant or Right, Expiration Term Interest rate, percentage point added to reference rate Debt Instrument, Basis Spread on Variable Rate Loss from remeasurement of development derivative liability Loss from remeasurement of development derivative liability Gain (Loss) From Remeasurement Of Derivative Liability Gain (Loss) From Remeasurement Of Derivative Liability Treasury stock, shares (in shares) Treasury Stock, Shares Sale of Stock [Domain] Sale of Stock [Domain] Revenue Revenue from Contract with Customer [Text Block] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Organization and Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Wacker Wacker [Member] Wacker. Proceeds from issuance of common stock in public offering, net Proceeds from Issuance Initial Public Offering Additional paid-in capital Additional Paid in Capital Class of Stock [Axis] Class of Stock [Axis] Foreign exchange (loss) gain Foreign Currency Transaction Gain (Loss), before Tax MedImmune Limited Med Immune Limited [Member] MedImmune limited. Cash and cash equivalents at the beginning of the period Cash and cash equivalents at the end of the period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Summary of Future Principal Payments Schedule of Maturities of Long-term Debt [Table Text Block] Debt instrument, maturity date Debt Instrument, Maturity Date Local Phone Number Local Phone Number Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Derivative [Line Items] Derivative [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Long-term debt Total principal payments Long-term Debt, Gross Depreciation Depreciation Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Prime Rate Prime Rate [Member] Entity Emerging Growth Company Entity Emerging Growth Company Purchase obligation, year 2022 through 2023 Purchase Obligation, to be Paid, Year Two and Three Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Achievement Of Certain Development And Intellectual Property Milestones Payment Upon Achievement Of Certain Development And Intellectual Property Milestones [Member] Payment Upon Achievement Of Certain Development And Intellectual Property Milestones [Member] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Maximum Maximum [Member] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Potential milestones payment Potential Milestones Payment Potential milestones payment Accumulated Deficit Retained Earnings [Member] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Grant Revenue Grant Revenue Revenue Recognition Policy Policy [Text Block] Grant revenue, revenue recognition policy. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Domain] Award Type [Domain] Silicon Valley Bank Silicon Valley Bank [Member] Silicon Valley Bank. Trading Symbol Trading Symbol Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Treasury stock, at cost, 29,967 shares as of March 31, 2021 and December 31, 2020 Treasury Stock, Value Computer hardware, software and telephone Office Equipment [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Thereafter Long-Term Debt, Maturity, after Year Two Long-Term Debt, Maturity, after Year Two Lab equipment Equipment [Member] Current liabilities: Liabilities, Current [Abstract] Entity Shell Company Entity Shell Company Fair Value Measurements on Recurring Basis Fair Value, Recurring [Member] Proceeds from lines of credit Proceeds from Lines of Credit Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Regulatory Agency [Domain] Regulatory Agency [Domain]